John French's questions to Clover Health Investments Corp (CLOV) leadership • Q3 2024
Question
John French of Leerink Partners asked how Clover Health incorporated the effects of the Inflation Reduction Act (IRA) into its 2025 plan bids, particularly concerning drug costs and overall plan viability.
Answer
CEO Andrew Toy stated that the company adjusted its bids to account for the IRA's phased-in changes, balancing subsidies and benefit levels. He noted that Clover Health successfully maintained a strong Part D offering, which he believes will be a competitive advantage as other plans have retreated in this area.